Merck KGaA Campral alcoholism treatment is in Phase III U.S. studies, firm tells UBS conference.
Executive Summary
MERCK KGaA ALCOHOLISM THERAPY CAMPRAL ON TRACK FOR 2000 LAUNCH in the U.S., Merck KGaA Chairman Hans Langmann told a UBS Securities life sciences conference in London April 16. Campral (acamprosate) is in Phase III trials in the U.S. Langmann maintained Campral has "blockbuster potential." The drug is marketed in seven European countries, with launches in three more expected this year, Langmann noted.